Clinical study on tuberactinomycin-n (TUM-N) and VIOMYCIN (VM) in retreatment of pulmonary tuberculosis

Abstract

The efficacy and the side-effects of Tuberactinomycin-N (TUM-N) in the retreatment of pulmonary tuberculosis were studied and compaired with those of Viomycin (VM). The drug resistance of tubercle bacilli isolated from the patients during treatment was also studied for TUM-N and VM. TUM-N is a new antituberculous drug isolated from the culture filtrate of Streptomyces griseoverticillatus var. tuberacticus (N 6-130 strain). This drug shows almost the same activity as VM for tubercle bacilli and one way cross resistance for kanamycin. In this study, two following regimens were allocated randomly for retreated patients. (1) TUM-N group: TUM-N was injected 1 g daily for the first three months, thereafter injected twice weekly. (45 cases) (2) VM group: VM was injected 1 g three times a week. (38 cases) If thereare previously unused drug, they were combined with TUM-N or VM. The results were summarized as follows; (1) TUM-N group showed slmost the same negative conversion rate on culture as VM group. (2) All of the cases treated with TUM-N combined with two previously unused drugs. showed 100% negative conversion rate on culture at 6 months. (3) The incidence of side-effects was lower in TUM-N group compared with VM group. The auditory disturbance was 2.2% in TUM-N group and 5.7% in VM group. The renal disturhance defined by the raise of BUN level over 20 mg/d/was observed in 23.7% among VM group while it was 10.9% in TUM-N group. The dropped-out cases due to side-effects were 3 (6.5%) among 46 cases of TUM-N group and 8(21.2%) among 38 cases of VM group (4) The criterion of drug resistance of TUM-N was examined and it was concluded that the growth on 1% Ogawa's media containing 100 mcg/ml TUM-N should be considered as resistant. © 1974, JAPANESE SOCIETY FOR TUBERCULOSIS. All rights reserved.